CD8A and rheumatoid arthritis: Thus the decreased ratio of CD4+ to CD8+ T cells and increased effector memory CD8+ T cells might be involved in the therapeutic mechanism of anti-CD154 antibody treatment, although further study is needed for characterization of effector memory CD8+ T cells and elucidation of its role in RA.